Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.81 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18664184 | 1.00 | MAOB (0.81) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL16841039 | 0.94 | MAOB (0.72) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL16604318 | 0.90 | MAOB (0.68) | MAOBRAB9AHRH3MAOACYP3A4 | |
| SCHEMBL14163886 | 0.90 | CYP2A6 (0.70) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL15038105 | 0.90 | MAOB (0.68) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL19962768 | 0.90 | MAOB (0.68) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL994803 | 0.90 | MAOB (0.68) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL2276512 | 0.90 | MAOB (0.68) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL14992823 | 0.90 | APP (0.74) | MAOBRAB9AHRH3APPMAOA | |
| SCHEMBL6980988 | 0.90 | MAOB (0.68) | MAOBRAB9AHRH3APPMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4603484-A2 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-119837855-A | Compounds for the treatment of bacterial infections and for the enhancement of antibiotics | 乔治亚州大学研究基金会 | 2025-04-18 | — | — | CN | disclosed |
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4076420-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114845708-A | Compounds for treating bacterial infections and enhancing antibiotics | 乔治亚州大学研究基金会 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | BPGM, MYD88, PGLS | MAOB 2129/4885RAB9A 2009/4885HRH3 2529/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | MAOB 2925/4885RAB9A 1309/4885HRH3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.